BrainStorm Cell Therapeutics Announces Upcoming Conference Call and Webinar on ALS Treatments
BrainStorm sets conference call for December 30, 2024, alongside a key webinar on ALS advancements scheduled for December 11, 2024.
NEW YORK, Dec. 9, 2024 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. BCLI, known for developing adult stem cell treatments for neurodegenerative diseases, announced a conference call and webcast on December 30, 2024, at 8:30 a.m. Eastern Time.
Chaim Lebovits, BrainStorm’s President and Chief Executive Officer, will lead the update. Joining him will be Hartoun Hartounian, PhD, Chief Operating Officer and EVP, and Bob Dagher, MD, Chief Development Officer. After the presentation, they will hold a Q&A session with investors.
Questions can be submitted in advance to q@brainstorm-cell.com by 10:00 a.m. Eastern Time on December 22, 2024.
Investors can join the conference call at the following numbers:
Investor dial in:
U.S. dial in: 888-506-0062
International: 973-528-0011
Participant Access Code: 225269
Webcast URL: https://www.webcaster4.com/Webcast/Page/2354/51756
For those unable to attend live, a replay of the conference call will be available until Monday, January 13, 2025.
Teleconference Replay Number:
Toll Free: 877-481-4010
International: 919-882-2331
Replay Passcode: 51756
Additionally, BrainStorm will conduct a Key Opinion Leader (KOL) Webinar titled “Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS)” on Wednesday, December 11, 2024, at 10:00 AM ET. The event will include a presentation by Dr. Terry Heiman Patterson, Director of the Center for Neurodegenerative Disorders at Temple University. Click here for registration details.
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. develops therapies for serious neurodegenerative diseases. The company specializes in both autologous and allogeneic cell therapies. It has exclusive rights to the NurOwn® technology platform, which generates autologous MSC-NTF cells that have Orphan Drug designations from the FDA and EMA for ALS. BrainStorm plans to launch a confirmatory Phase 3b trial for NurOwn to further study its safety and effectiveness. The company has made significant advancements, including a Phase 3 trial for NurOwn in ALS and ongoing trials for progressive multiple sclerosis (MS) funded by grants from the California Institute for Regenerative Medicine (CIRM) and the National MS Society (NMSS).
Notice Regarding Forward-Looking Statements
This press release contains “forward-looking statements” that come with considerable risks and uncertainties, including expectations of BrainStorm’s common stock listing on The Nasdaq Capital Market. Statements not strictly historical are considered forward-looking and often use terms such as “anticipate,” “believe,” or “expect.” The risks are outlined further in BrainStorm’s annual report on Form 10-K and quarterly reports on Form 10-Q, available at http://www.sec.gov. The company does not commit to updating any forward-looking statements unless legally required, despite believing these expectations to be reasonable.
“`html
BrainStorm Cell Therapeutics Provides Key Updates on NurOwn and Future Directions
This press release features important “forward-looking statements” that involve significant risks and uncertainties. These uncertainties include the clinical progress of NurOwn as a potential treatment for ALS, the future availability of NurOwn for patients, and the overall success of BrainStorm Cell Therapeutics. Any statements made, apart from those relaying historical facts, are forward-looking in nature. This can be identified by the use of terms such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negatives of these words or other equivalent expressions, although not every forward-looking statement employs these terms.
These statements reflect BrainStorm Cell Therapeutics’ current expectations and are influenced by inherent uncertainties, risks, and assumptions that are difficult to predict. Key risks encompass management’s capability to accomplish its objectives, the company’s ability to secure additional funding, and whether BrainStorm Cell Therapeutics can sustain operations. Moreover, future regulatory approval prospects for NurOwn, the outcome of interactions with the FDA, and various other factors highlighted in BrainStorm’s annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov pose significant uncertainties.
Readers should evaluate these factors thoroughly and avoid placing undue trust in these projections. Forward-looking statements are based on the management’s beliefs, expectations, and opinions as of the release date. BrainStorm Cell Therapeutics does not take responsibility for updating these statements unless required by law, regardless of significant changes in circumstances or management expectations. While the expectations underlying forward-looking statements seem reasonable, actual future results, performance, and achievements cannot be assured.
CONTACTS
IR:
Michael Wood
Phone: +1 646-597-6983
Email: mwood@lifesciadvisors.com
SOURCE BrainStorm Cell Therapeutics Inc.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
“`
